A unique vectored vaccine
The FIRST and ONLY vaccine that protects against the three serious and widespread viral diseases amongst rabbits: myxomatosis and rabbit hemorrhagic disease caused by both classic (RHDV-1) and variant (RHDV-2) strains.
Broad spectrum cover against myxomatosis, classic and variant strains of RHD:
- 12 month duration of immunity
- 0.5 ml volume vaccine
- Fully licensed for use in pregnancy
- Single primary dose
- Reduced visits to practice
- Improved convenience
- Enhanced compliance
Dual-vector technology:
- Non-adjuvated vaccine
- Stimulation of both humoral and cell-mediated immunity
- No requirement for live rabbits during manufacturing
- The attenuated myxoma strain disabled by the inactivation of two virulence genes: MGF and M11L
Clinical efficacy studies
-
Challenge study against myxomatosis1
- 11 vaccinates, 5 unvaccinated controls (4-5 weeks old)
- Vaccinated with a minimum titre dose of Nobivac® Myxo-RHD
- All rabbits were challenged at 24 days post-vaccination with a virulent myxoma virus strain
Results
- All controls developed signs of myxomatosis
- 1 vaccinate developed acute enteritis (mucoid enteropathy) unrelated to the myxoma virus challenge
- All other vaccinates were free of clinical signs except for minor rectal temperature fluctuations
-
Challenge study against RHDV-1 and RHDV-22
- 45 rabbits divided into six groups
- Vaccinated with a minimum titre dose of Nobivac Myxo-RHD PLUS or solvent, at either 5 weeks or 9 weeks of age, as shown below
- Challenged 3 weeks or 7 weeks after vaccination with either RHDV-1 or RHDV-2, as shown below
Results
- All controls showed severe signs of RHD within three days of challange
- All vaccinates survived and none showed any clinical signs of RHD
Nobivac® Myxo-RHD PLUS contains live myxoma vectored RHD virus strain 009 and MK 1898. POM-V
Nobivac® Myxo-RHD contains live myxoma vectored RHD virus strain 009. POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
MSD Animal Health UK Limited, Walton Manor, Walton, Milton Keynes, MK7 7AJ, UK
Registered in England & Wales no. 946942
References
1. Spibey N, McCabe VJ, Greenwood NM, Jack SC, Sutton D, van der Waart L. Novel bivalent vectored vaccine for control of myxomatosis and rabbit haemorrhagic disease. Vet Rec. 2012;170:309.
2. Data on file, Study Report 18R/0118, MSD Animal Health.
